Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans - PubMed (original) (raw)
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
R Stephanie Huang et al. Mol Cancer Ther. 2008 Sep.
Abstract
To gain a better understanding of the genetic variants associated with carboplatin-induced cytotoxicity in individuals of African descent, we present a step-wise approach integrating genotypes, gene expression, and sensitivity of HapMap cell lines to carboplatin. Cell lines derived from 30 trios of African descent (YRI) were used to develop a preclinical model to identify genetic variants and gene expression that contribute to carboplatin-induced cytotoxicity. Cytotoxicity was determined as cell growth inhibition at increasing concentrations of carboplatin for 72 h. Gene expression of 89 HapMap YRI cell lines was determined using the Affymetrix GeneChip Human Exon 1.0 ST Array. Single nucleotide polymorphism genotype and the percent survival at different treatment concentrations along with carboplatin IC50 were linked through whole genome association. A second association test was done between single nucleotide polymorphism genotype and gene expression, and linear regression was then used to capture those genes whose expression correlated to drug sensitivity phenotypes. This approach allows us to identify genetic variants that significantly associate with sensitivity to the cytotoxic effects of carboplatin through their effect on gene expression. We found a gene (GPC5) whose expression is important in all carboplatin treatment concentrations as well as many genes unique to either low (e.g., MAPK1) or high (e.g., BRAF, MYC, and BCL2L1) concentrations of drug. Our whole genome approach enables us to evaluate the contribution of genetic and gene expression variation to a wide range of cellular phenotypes. The identification of concentration specific genetic signatures allows for potential integration of pharmacokinetics, pharmacodynamics, and pharmacogenetics in tailoring chemotherapy.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
Dr. Dolan has presented seminars at Affymetrix funded meetings. The other authors reported no potential conflicts of interest.
Figures
Figure 1. Relationship between rs1031324, GPC5 gene expression, and carboplatin IC50 in the YRI samples
A, rs1031324 genotype and log2-transformed carboplatin IC50 association. B, rs1031324 genotype and log2-transformed GPC5 expression association. C, log2-transformed GPC5 expression and log2-transformed carboplatin IC50 correlation.
Figure 2. Relationship between rs3821666, MAPK1 gene expression, and percent survival after 10 µmol/L carboplatin treatment in the YRI samples
A, rs3821666 genotype and log2-transformed percent survival after 10 µmol/L carboplatin treatment association. B, rs3821666 genotype and log2-transformed MAPK1 expression association. C, log2-transformed MAPK1 expression and log2-transformed percent survival after 10 µmol/L carboplatin treatment correlation.
Figure 3. Relationship between rs11993726, BRAF gene expression, and percent survival after 40 µmol/L carboplatin treatment in the YRI samples
A, rs11993726 genotype and log2-transformed percent survival after 40 µmol/L carboplatin treatment association. B, rs11993726 genotype and log2-transformed BRAF expression association. C, log2-transformed BRAF expression and log2-transformed percent survival after 40 µmol/L carboplatin treatment correlation.
Similar articles
- A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. Huang RS, et al. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63. doi: 10.1073/pnas.0703736104. Epub 2007 May 30. Proc Natl Acad Sci U S A. 2007. PMID: 17537913 Free PMC article. - Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.
Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME. Huang RS, et al. Am J Hum Genet. 2007 Sep;81(3):427-37. doi: 10.1086/519850. Epub 2007 Aug 1. Am J Hum Genet. 2007. PMID: 17701890 Free PMC article. - Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Stephanie Huang R, Eileen Dolan M. O'Donnell PH, et al. Pharmacogenet Genomics. 2010 May;20(5):327-37. doi: 10.1097/FPC.0b013e3283396c4e. Pharmacogenet Genomics. 2010. PMID: 20393316 Free PMC article. - Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.
Li R, Kim D, Wheeler HE, Dudek SM, Dolan ME, Ritchie MD. Li R, et al. Pharmacogenomics J. 2019 Apr;19(2):178-190. doi: 10.1038/s41397-018-0024-6. Epub 2018 May 25. Pharmacogenomics J. 2019. PMID: 29795408 - Molecular genetic studies of complex phenotypes.
Marian AJ. Marian AJ. Transl Res. 2012 Feb;159(2):64-79. doi: 10.1016/j.trsl.2011.08.001. Epub 2011 Aug 31. Transl Res. 2012. PMID: 22243791 Free PMC article. Review.
Cited by
- Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.
Mulford AJ, Wing C, Dolan ME, Wheeler HE. Mulford AJ, et al. Hum Mol Genet. 2021 Apr 26;30(3-4):305-317. doi: 10.1093/hmg/ddab029. Hum Mol Genet. 2021. PMID: 33575800 Free PMC article. - Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure.
Norton N, Crook JE, Wang L, Olson JE, Kachergus JM, Serie DJ, Necela BM, Borgman PG, Advani PP, Ray JC, Landolfo C, Di Florio DN, Hill AR, Bruno KA, Fairweather D. Norton N, et al. Front Cardiovasc Med. 2020 Aug 13;7:142. doi: 10.3389/fcvm.2020.00142. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32903434 Free PMC article. - The influence of Neanderthal alleles on cytotoxic response.
Akhtari FS, Havener TM, Fukudo M, Jack JR, McLeod HL, Wiltshire T, Motsinger-Reif AA. Akhtari FS, et al. PeerJ. 2018 Oct 23;6:e5691. doi: 10.7717/peerj.5691. eCollection 2018. PeerJ. 2018. PMID: 30386687 Free PMC article. - Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.
Li L, Zhang JW, Jenkins G, Xie F, Carlson EE, Fridley BL, Bamlet WR, Petersen GM, McWilliams RR, Wang L. Li L, et al. Pharmacogenet Genomics. 2016 Dec;26(12):527-537. doi: 10.1097/FPC.0000000000000241. Pharmacogenet Genomics. 2016. PMID: 27749787 Free PMC article. - Utility of Lymphoblastoid Cell Lines for Induced Pluripotent Stem Cell Generation.
Kumar S, Curran JE, Glahn DC, Blangero J. Kumar S, et al. Stem Cells Int. 2016;2016:2349261. doi: 10.1155/2016/2349261. Epub 2016 Jun 7. Stem Cells Int. 2016. PMID: 27375745 Free PMC article.
References
- Langer C, Millenson M, Rosvold E, et al. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. Semin Oncol. 1997;24:S12–81–S12–88. - PubMed
- Micheletti E, La Face B, Bianchi E, et al. Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB–IIIB (UICC): a phase I/II and pharmacokinetic study. Am J Clin Oncol. 1997;20:613–620. - PubMed
- Shimizu T, Yoshida M, Makishima K. Importance of AUC of carboplatin in head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho. 1998;101:259–265. - PubMed
- Mercier C, Ciccolini J, Pourroy B, et al. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit. 2006;28:212–218. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 CA 125183/CA/NCI NIH HHS/United States
- U01 GM061393-090005/GM/NIGMS NIH HHS/United States
- P50 CA125183/CA/NCI NIH HHS/United States
- U01 GM061393-090010/GM/NIGMS NIH HHS/United States
- U01 GM061393-070005/GM/NIGMS NIH HHS/United States
- T32 GM007019/GM/NIGMS NIH HHS/United States
- U01 GM061393-100010/GM/NIGMS NIH HHS/United States
- U01GM61374/GM/NIGMS NIH HHS/United States
- U01 GM061393-070010/GM/NIGMS NIH HHS/United States
- U01 GM061393-060005/GM/NIGMS NIH HHS/United States
- U01 GM061393-100005/GM/NIGMS NIH HHS/United States
- P50 CA125183-020004/CA/NCI NIH HHS/United States
- U01 GM061393-10S10005/GM/NIGMS NIH HHS/United States
- U01 GM061393/GM/NIGMS NIH HHS/United States
- P50 CA125183-030004/CA/NCI NIH HHS/United States
- U01GM61393/GM/NIGMS NIH HHS/United States
- P50 CA125183-040004/CA/NCI NIH HHS/United States
- P50 CA125183-010004/CA/NCI NIH HHS/United States
- U01 GM061393-080005/GM/NIGMS NIH HHS/United States
- U01 GM061393-10S10010/GM/NIGMS NIH HHS/United States
- U01 GM061374/GM/NIGMS NIH HHS/United States
- U01 GM061393-060010/GM/NIGMS NIH HHS/United States
- U01 GM061393-080010/GM/NIGMS NIH HHS/United States
- 5 T32 GM 007019-30/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous